entertainment -WSS

entertainment

author：comprehensive 2025-10-02 19:20:15 - browse：8217

Sen. Bob Menendez (D-N.J.) Michael M. Santiago/Getty Images

WASHINGTON — With mounting calls for embattled Sen. Bob Menendez to resign, the pharmaceutical industry could see one of its historical, and increasingly rare, Democratic allies ousted from Congress.

The New Jersey senator is embroiled in another financial scandal after last week’s indictment over hundreds of thousands of dollars he and his wife allegedly accepted to influence military aid. The charges — which Menendez insists he will beat — come roughly seven years after he was accused of pressuring Medicare officials to resolve a dispute in favor of a lavish political donor. That case ended in a hung jury.

But this time around, Capitol lawmakers and New Jersey Democrats including Sen. Cory Booker, a longtime legislation partner, are calling on Menendez to resign. The mounting pressure and looming court battle spell out a hazy future for one of the pharmaceutical industry’s biggest allies in the Democratic Party.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Citing H5N1 threat, CDC urges peak flu monitoring this summer

Wikipedia

WSS

3 hurdles to bringing medical devices to the U.S. market

Digital health: a case of mistaken identity

The battle over the Brookhaven Landfill on Long Island

Why drug prescriptions should include diagnoses

H5N1 virus can be tracked in retail milk, scientists say

Cloning humans is technically possible. It's curious no one has tried

focus

entertainment

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

UnitedHealth argues against case alleging wrongful AI care denials

Medical leaders decry Supreme Court decision on affirmative action

Scrutiny of post

Hepatitis C has a cure — but many Americans still lack access to it

#NeedHerScience: shining a light on gender disparities in medicine

Heart attack and stroke risk calculators need revising

Fentanyl is making it harder to start addiction treatment

Medicare proposal to cover medical devices draws a mixed reaction

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

explore

Liver decline slowed by off

Why drug prescriptions should include diagnoses

The strategy behind pharma's lawsuits over drug pricing reform

Biogen joins immunology wave with $1.15 billion acquisition of HI

Paxlovid study fails to answer questions over benefit for broader groups

The strategy behind pharma's lawsuits over drug pricing reform

knowledge

Wikipedia

focus

focus